Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
Identifieur interne : 000220 ( Istex/Corpus ); précédent : 000219; suivant : 000221Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
Auteurs : Pramote Tragulpiankit ; Suvatna Chulavatnatol ; Ticha Rerkpattanapipat ; Suchela Janwityanujit ; Suthatip Somjarit ; Uamporn SirikhedgonSource :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2012-06.
English descriptors
- Teeft :
- Ade, Adverse drug event, Adverse drug events, Adverse drug reactions, Adverse event, Adverse events, Adverse reactions, Ambulatory, Ambulatory care, Ambulatory patients, Antirheumatic drug, Best pract, Cardiovascular agents, Causality, Causality assessment, Clin epidemiol, Clin rheumatol, Coexisting diseases, Current visit, Direct patient interview, Disease state, Dmards, Drug change, Drug events, Drug groups, Elderly patients, Frequent drug groups, Gastrointestinal tract, High rate, Higher rate, Hosp pharm, International journal, Last hospital visit, Liver injuries, Lower prevalence, Mahidol university, Nsaid, Oral contraceptives, Oral corticosteroids, Organ systems, Osteoarthritis, Other studies, Other treatment, Pathophysiologic approach, Patient education, Patient outcome, Permanent harm, Pharmacist, Preventability, Preventability assessment, Preventable, Preventable ades, Ramathibodi hospital, Research pharmacist, Rheumatic, Rheumatic disease, Rheumatic diseases, Rheumatoid arthritis, Rheumatologist, Rheumatology clinics, Severity level, Study period, Systematic review, Therapeutic drug monitoring.
Abstract
Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.
Url:
DOI: 10.1111/j.1756-185X.2012.01716.x
Links to Exploration step
ISTEX:EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><author><name sortKey="Tragulpiankit, Pramote" sort="Tragulpiankit, Pramote" uniqKey="Tragulpiankit P" first="Pramote" last="Tragulpiankit">Pramote Tragulpiankit</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation><affiliation><mods:affiliation>: Asst Prof Pramote Tragulpiankit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri‐Ayudhaya Road, Bangkok 10400, Thailand.Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: pyptg@mahidol.ac.th</mods:affiliation></affiliation></author><author><name sortKey="Chulavatnatol, Suvatna" sort="Chulavatnatol, Suvatna" uniqKey="Chulavatnatol S" first="Suvatna" last="Chulavatnatol">Suvatna Chulavatnatol</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author><author><name sortKey="Rerkpattanapipat, Ticha" sort="Rerkpattanapipat, Ticha" uniqKey="Rerkpattanapipat T" first="Ticha" last="Rerkpattanapipat">Ticha Rerkpattanapipat</name><affiliation><mods:affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</mods:affiliation></affiliation></author><author><name sortKey="Janwityanujit, Suchela" sort="Janwityanujit, Suchela" uniqKey="Janwityanujit S" first="Suchela" last="Janwityanujit">Suchela Janwityanujit</name><affiliation><mods:affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</mods:affiliation></affiliation></author><author><name sortKey="Somjarit, Suthatip" sort="Somjarit, Suthatip" uniqKey="Somjarit S" first="Suthatip" last="Somjarit">Suthatip Somjarit</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author><author><name sortKey="Sirikhedgon, Uamporn" sort="Sirikhedgon, Uamporn" uniqKey="Sirikhedgon U" first="Uamporn" last="Sirikhedgon">Uamporn Sirikhedgon</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1756-185X.2012.01716.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000220</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000220</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><author><name sortKey="Tragulpiankit, Pramote" sort="Tragulpiankit, Pramote" uniqKey="Tragulpiankit P" first="Pramote" last="Tragulpiankit">Pramote Tragulpiankit</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation><affiliation><mods:affiliation>: Asst Prof Pramote Tragulpiankit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri‐Ayudhaya Road, Bangkok 10400, Thailand.Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: pyptg@mahidol.ac.th</mods:affiliation></affiliation></author><author><name sortKey="Chulavatnatol, Suvatna" sort="Chulavatnatol, Suvatna" uniqKey="Chulavatnatol S" first="Suvatna" last="Chulavatnatol">Suvatna Chulavatnatol</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author><author><name sortKey="Rerkpattanapipat, Ticha" sort="Rerkpattanapipat, Ticha" uniqKey="Rerkpattanapipat T" first="Ticha" last="Rerkpattanapipat">Ticha Rerkpattanapipat</name><affiliation><mods:affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</mods:affiliation></affiliation></author><author><name sortKey="Janwityanujit, Suchela" sort="Janwityanujit, Suchela" uniqKey="Janwityanujit S" first="Suchela" last="Janwityanujit">Suchela Janwityanujit</name><affiliation><mods:affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</mods:affiliation></affiliation></author><author><name sortKey="Somjarit, Suthatip" sort="Somjarit, Suthatip" uniqKey="Somjarit S" first="Suthatip" last="Somjarit">Suthatip Somjarit</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author><author><name sortKey="Sirikhedgon, Uamporn" sort="Sirikhedgon, Uamporn" uniqKey="Sirikhedgon U" first="Uamporn" last="Sirikhedgon">Uamporn Sirikhedgon</name><affiliation><mods:affiliation>Faculty of Pharmacy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="315">315</biblScope><biblScope unit="page" to="321">321</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2012-06">2012-06</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Ade</term><term>Adverse drug event</term><term>Adverse drug events</term><term>Adverse drug reactions</term><term>Adverse event</term><term>Adverse events</term><term>Adverse reactions</term><term>Ambulatory</term><term>Ambulatory care</term><term>Ambulatory patients</term><term>Antirheumatic drug</term><term>Best pract</term><term>Cardiovascular agents</term><term>Causality</term><term>Causality assessment</term><term>Clin epidemiol</term><term>Clin rheumatol</term><term>Coexisting diseases</term><term>Current visit</term><term>Direct patient interview</term><term>Disease state</term><term>Dmards</term><term>Drug change</term><term>Drug events</term><term>Drug groups</term><term>Elderly patients</term><term>Frequent drug groups</term><term>Gastrointestinal tract</term><term>High rate</term><term>Higher rate</term><term>Hosp pharm</term><term>International journal</term><term>Last hospital visit</term><term>Liver injuries</term><term>Lower prevalence</term><term>Mahidol university</term><term>Nsaid</term><term>Oral contraceptives</term><term>Oral corticosteroids</term><term>Organ systems</term><term>Osteoarthritis</term><term>Other studies</term><term>Other treatment</term><term>Pathophysiologic approach</term><term>Patient education</term><term>Patient outcome</term><term>Permanent harm</term><term>Pharmacist</term><term>Preventability</term><term>Preventability assessment</term><term>Preventable</term><term>Preventable ades</term><term>Ramathibodi hospital</term><term>Research pharmacist</term><term>Rheumatic</term><term>Rheumatic disease</term><term>Rheumatic diseases</term><term>Rheumatoid arthritis</term><term>Rheumatologist</term><term>Rheumatology clinics</term><term>Severity level</term><term>Study period</term><term>Systematic review</term><term>Therapeutic drug monitoring</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>ade</json:string><json:string>preventable</json:string><json:string>nsaid</json:string><json:string>dmards</json:string><json:string>causality</json:string><json:string>preventability</json:string><json:string>preventable ades</json:string><json:string>research pharmacist</json:string><json:string>rheumatologist</json:string><json:string>adverse drug events</json:string><json:string>adverse events</json:string><json:string>rheumatic diseases</json:string><json:string>causality assessment</json:string><json:string>osteoarthritis</json:string><json:string>international journal</json:string><json:string>rheumatoid arthritis</json:string><json:string>ambulatory patients</json:string><json:string>ambulatory</json:string><json:string>pharmacist</json:string><json:string>adverse drug reactions</json:string><json:string>other treatment</json:string><json:string>study period</json:string><json:string>drug change</json:string><json:string>drug events</json:string><json:string>systematic review</json:string><json:string>therapeutic drug monitoring</json:string><json:string>permanent harm</json:string><json:string>adverse reactions</json:string><json:string>oral corticosteroids</json:string><json:string>preventability assessment</json:string><json:string>rheumatic</json:string><json:string>cardiovascular agents</json:string><json:string>ramathibodi hospital</json:string><json:string>higher rate</json:string><json:string>drug groups</json:string><json:string>current visit</json:string><json:string>lower prevalence</json:string><json:string>mahidol university</json:string><json:string>clin epidemiol</json:string><json:string>disease state</json:string><json:string>last hospital visit</json:string><json:string>direct patient interview</json:string><json:string>liver injuries</json:string><json:string>adverse drug event</json:string><json:string>rheumatology clinics</json:string><json:string>organ systems</json:string><json:string>gastrointestinal tract</json:string><json:string>coexisting diseases</json:string><json:string>severity level</json:string><json:string>antirheumatic drug</json:string><json:string>elderly patients</json:string><json:string>other studies</json:string><json:string>adverse event</json:string><json:string>frequent drug groups</json:string><json:string>patient outcome</json:string><json:string>high rate</json:string><json:string>patient education</json:string><json:string>best pract</json:string><json:string>clin rheumatol</json:string><json:string>rheumatic disease</json:string><json:string>pathophysiologic approach</json:string><json:string>ambulatory care</json:string><json:string>hosp pharm</json:string><json:string>oral contraceptives</json:string></teeft></keywords><author><json:item><name>Pramote Tragulpiankit</name><affiliations><json:string>Faculty of Pharmacy</json:string><json:string>: Asst Prof Pramote Tragulpiankit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri‐Ayudhaya Road, Bangkok 10400, Thailand.Email:</json:string><json:string>E-mail: pyptg@mahidol.ac.th</json:string></affiliations></json:item><json:item><name>Suvatna Chulavatnatol</name><affiliations><json:string>Faculty of Pharmacy</json:string></affiliations></json:item><json:item><name>Ticha Rerkpattanapipat</name><affiliations><json:string>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</json:string></affiliations></json:item><json:item><name>Suchela Janwityanujit</name><affiliations><json:string>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</json:string></affiliations></json:item><json:item><name>Suthatip Somjarit</name><affiliations><json:string>Faculty of Pharmacy</json:string></affiliations></json:item><json:item><name>Uamporn Sirikhedgon</name><affiliations><json:string>Faculty of Pharmacy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>adverse drug events</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>osteoarthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>outpatients</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prevalence</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rheumatoid arthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Thailand</value></json:item></subject><articleId><json:string>APL1716</json:string></articleId><arkIstex>ark:/67375/WNG-F45C55KV-V</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.</abstract><qualityIndicators><score>8.442</score><pdfWordCount>3586</pdfWordCount><pdfCharCount>23768</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595.276 x 779.528 pts</pdfPageSize><pdfWordsPerPage>512</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>238</abstractWordCount><abstractCharCount>1591</abstractCharCount><keywordCount>6</keywordCount></qualityIndicators><title>Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><pmid><json:string>22709494</json:string></pmid><genre><json:string>article</json:string></genre><host><title>International Journal of Rheumatic Diseases</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1756-185X</json:string></doi><issn><json:string>1756-1841</json:string></issn><eissn><json:string>1756-185X</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>15</volume><issue>3</issue><pages><first>315</first><last>321</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Article</value></json:item><json:item><value>Original articles</value></json:item></subject></host><namedEntities><unitex><date><json:string>2012-01-09</json:string></date><geogName></geogName><orgName><json:string>Blackwell Publishing Asia Pty Ltd</json:string><json:string>SPSS Inc., Chicago</json:string><json:string>Ethical Board Committee of Ramathibodi Hospital</json:string><json:string>Department Hospital, Thailand</json:string><json:string>Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri-Ayudhaya Road, Bangkok</json:string><json:string>The Authors International Journal</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Asia Paci</json:string><json:string>Thomsen</json:string><json:string>Harwig</json:string><json:string>Gurwitz</json:string><json:string>Hartwig</json:string><json:string>Gandhi</json:string><json:string>Pramote Tragulpiankit</json:string></persName><placeName><json:string>Thailand</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>P. Tragulpiankit et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-F45C55KV-V</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - sante publique. hygiene-medecine du travail</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1111/j.1756-185X.2012.01716.x</json:string></doi><id>EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2012 The Authors International Journal of Rheumatic Diseases © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd</licence></availability><date type="published" when="2012-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Pramote</forename><surname>Tragulpiankit</surname></persName><affiliation><orgName type="institution">Faculty of Pharmacy</orgName></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Suvatna</forename><surname>Chulavatnatol</surname></persName><affiliation><orgName type="institution">Faculty of Pharmacy</orgName></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Ticha</forename><surname>Rerkpattanapipat</surname></persName><affiliation><orgName type="institution">Faculty of Medicine</orgName>
<orgName type="institution">Allergy Immunology and Rheumatology Unit</orgName>
<orgName type="institution">Ramathibodi Hospital</orgName>
<orgName type="institution">Mahidol University</orgName>
<address><settlement>Bangkok</settlement>
<country key="TH" xml:lang="en">THAILAND</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Suchela</forename><surname>Janwityanujit</surname></persName><affiliation><orgName type="institution">Faculty of Medicine</orgName>
<orgName type="institution">Allergy Immunology and Rheumatology Unit</orgName>
<orgName type="institution">Ramathibodi Hospital</orgName>
<orgName type="institution">Mahidol University</orgName>
<address><settlement>Bangkok</settlement>
<country key="TH" xml:lang="en">THAILAND</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Suthatip</forename><surname>Somjarit</surname></persName><affiliation><orgName type="institution">Faculty of Pharmacy</orgName></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Uamporn</forename><surname>Sirikhedgon</surname></persName><affiliation><orgName type="institution">Faculty of Pharmacy</orgName></affiliation></author><idno type="istex">EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199</idno><idno type="ark">ark:/67375/WNG-F45C55KV-V</idno><idno type="DOI">10.1111/j.1756-185X.2012.01716.x</idno><idno type="unit">APL1716</idno><idno type="toTypesetVersion">file:APL.APL1716.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="pISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><idno type="book-DOI">10.1111/(ISSN)1756-185X</idno><idno type="book-part-DOI">10.1111/apl.2012.15.issue-3</idno><idno type="product">APL</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="315">315</biblScope><biblScope unit="page" to="321">321</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2012-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main" xml:id="apl1716-abs-0001"><head>Abstract</head><head>Aim</head><p>We aimed to determine the prevalence and characteristics of adverse drug events (<hi rend="fc">ADE</hi>) in rheumatoid arthritis (<hi rend="fc">RA</hi>) and (osteoarthritis) <hi rend="fc">OA</hi> patients.</p><head>Method</head><p>A cross‐sectional study at rheumatology clinics, was performed by random selection of <hi rend="fc">RA</hi> and <hi rend="fc">OA</hi> out‐patients by a research pharmacist. All suspected <hi rend="fc">ADE</hi>s occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. <hi rend="fc">ADE</hi> characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded.</p><head>Results</head><p>One hundred and forty‐three patients consisting of 129 <hi rend="fc">RA</hi> and 14 <hi rend="fc">OA</hi> were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 <hi rend="fc">ADE</hi>s were detected in 51 patients. The prevalence and rate of <hi rend="fc">ADE</hi> were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 <hi rend="fc">ADE</hi>s (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in <hi rend="fc">ADE</hi>s by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 <hi rend="fc">ADE</hi>s (61.8%), classified as severity level 1 and 2a‐b, and 43 <hi rend="fc">ADE</hi>s (63.2%) were completely or partially resolved during the study period.</p><head>Conclusion</head><p><hi rend="fc">ADE</hi>s are common in <hi rend="fc">RA</hi> and <hi rend="fc">OA</hi> patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of <hi rend="fc">ADE</hi> in these patients.</p></abstract><textClass><keywords><term xml:id="apl1716-kwd-0001">adverse drug events</term><term xml:id="apl1716-kwd-0002">osteoarthritis</term><term xml:id="apl1716-kwd-0003">outpatients</term><term xml:id="apl1716-kwd-0004">prevalence</term><term xml:id="apl1716-kwd-0005">rheumatoid arthritis</term><term xml:id="apl1716-kwd-0006">Thailand</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords><keywords rend="tocHeading1"><term>Original articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="apl1716" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1756-185X</doi><issn type="print">1756-1841</issn><issn type="electronic">1756-185X</issn><idGroup><id type="product" value="APL"></id></idGroup><titleGroup><title sort="INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES" type="main">International Journal of Rheumatic Diseases</title><title type="short">Int J Rheum Dis</title></titleGroup></publicationMeta><publicationMeta level="part" position="06103"><doi origin="wiley">10.1111/apl.2012.15.issue-3</doi><copyright ownership="publisher">Journal compilation © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd</copyright><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2012-06">June 2012</coverDate></publicationMeta><publicationMeta level="unit" position="11" status="forIssue" type="article"><doi>10.1111/j.1756-185X.2012.01716.x</doi><idGroup><id type="unit" value="APL1716"></id></idGroup><countGroup><count number="7" type="pageTotal"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original articles</title></titleGroup><copyright ownership="joint">© 2012 The Authors International Journal of Rheumatic Diseases © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd</copyright><eventGroup><event agent="SPS" date="2012-01-09" type="xmlCreated"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-02-13"></event><event type="firstOnline" date="2012-02-13"></event><event type="publishedOnlineFinalForm" date="2012-06-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-25"></event></eventGroup><numberingGroup><numbering type="pageFirst">315</numbering><numbering type="pageLast">321</numbering></numberingGroup><correspondenceTo><lineatedText><line><i>Correspondence</i>: Asst Prof Pramote Tragulpiankit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri‐Ayudhaya Road, Bangkok 10400, Thailand.</line><line>Email: <email>pyptg@mahidol.ac.th</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APL.APL1716.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title><title type="shortAuthors">P. Tragulpiankit <i>et al</i>.</title></titleGroup><creators><creator affiliationRef="#apl1716-aff-0001" corresponding="yes" creatorRole="author" xml:id="apl1716-cr-0001"><personName><givenNames>Pramote</givenNames> <familyName>Tragulpiankit</familyName></personName></creator><creator affiliationRef="#apl1716-aff-0001" creatorRole="author" xml:id="apl1716-cr-0002"><personName><givenNames>Suvatna</givenNames> <familyName>Chulavatnatol</familyName></personName></creator><creator affiliationRef="#apl1716-aff-0002" creatorRole="author" xml:id="apl1716-cr-0003"><personName><givenNames>Ticha</givenNames> <familyName>Rerkpattanapipat</familyName></personName></creator><creator affiliationRef="#apl1716-aff-0002" creatorRole="author" xml:id="apl1716-cr-0004"><personName> <givenNames>Suchela</givenNames> <familyName>Janwityanujit</familyName></personName></creator><creator affiliationRef="#apl1716-aff-0001" creatorRole="author" xml:id="apl1716-cr-0005"><personName><givenNames>Suthatip</givenNames> <familyName>Somjarit</familyName></personName></creator><creator affiliationRef="#apl1716-aff-0001" creatorRole="author" xml:id="apl1716-cr-0006"><personName> <givenNames>Uamporn</givenNames> <familyName>Sirikhedgon</familyName></personName></creator></creators><affiliationGroup><affiliation type="organization" xml:id="apl1716-aff-0001"><orgName>Faculty of Pharmacy</orgName></affiliation><affiliation countryCode="TH" type="organization" xml:id="apl1716-aff-0002"><orgName>Faculty of Medicine</orgName> <orgName>Allergy Immunology and Rheumatology Unit</orgName> <orgName>Ramathibodi Hospital</orgName> <orgName>Mahidol University</orgName> <address><city>Bangkok</city> <country>Thailand</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="apl1716-kwd-0001">adverse drug events</keyword><keyword xml:id="apl1716-kwd-0002">osteoarthritis</keyword><keyword xml:id="apl1716-kwd-0003">outpatients</keyword><keyword xml:id="apl1716-kwd-0004">prevalence</keyword><keyword xml:id="apl1716-kwd-0005">rheumatoid arthritis</keyword><keyword xml:id="apl1716-kwd-0006">Thailand</keyword></keywordGroup><abstractGroup><abstract type="main" xml:id="apl1716-abs-0001" xml:lang="en"><title type="main">Abstract</title><section xml:id="apl1716-sec-0001"><title type="main">Aim</title><p>We aimed to determine the prevalence and characteristics of adverse drug events (<fc>ADE</fc>) in rheumatoid arthritis (<fc>RA</fc>) and (osteoarthritis) <fc>OA</fc> patients.</p></section><section xml:id="apl1716-sec-0002"><title type="main">Method</title><p>A cross‐sectional study at rheumatology clinics, was performed by random selection of <fc>RA</fc> and <fc>OA</fc> out‐patients by a research pharmacist. All suspected <fc>ADE</fc>s occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. <fc>ADE</fc> characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded.</p></section><section xml:id="apl1716-sec-0003"><title type="main">Results</title><p>One hundred and forty‐three patients consisting of 129 <fc>RA</fc> and 14 <fc>OA</fc> were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 <fc>ADE</fc>s were detected in 51 patients. The prevalence and rate of <fc>ADE</fc> were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 <fc>ADE</fc>s (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in <fc>ADE</fc>s by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 <fc>ADE</fc>s (61.8%), classified as severity level 1 and 2a‐b, and 43 <fc>ADE</fc>s (63.2%) were completely or partially resolved during the study period.</p></section><section xml:id="apl1716-sec-0004"><title type="main">Conclusion</title><p><fc>ADE</fc>s are common in <fc>RA</fc> and <fc>OA</fc> patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of <fc>ADE</fc> in these patients.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients</title></titleInfo><name type="personal"><namePart type="given">Pramote</namePart><namePart type="family">Tragulpiankit</namePart><affiliation>Faculty of Pharmacy</affiliation><affiliation>: Asst Prof Pramote Tragulpiankit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri‐Ayudhaya Road, Bangkok 10400, Thailand.Email:</affiliation><affiliation>E-mail: pyptg@mahidol.ac.th</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Suvatna</namePart><namePart type="family">Chulavatnatol</namePart><affiliation>Faculty of Pharmacy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ticha</namePart><namePart type="family">Rerkpattanapipat</namePart><affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Suchela</namePart><namePart type="family">Janwityanujit</namePart><affiliation>Faculty of Medicine, Allergy Immunology and Rheumatology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Suthatip</namePart><namePart type="family">Somjarit</namePart><affiliation>Faculty of Pharmacy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Uamporn</namePart><namePart type="family">Sirikhedgon</namePart><affiliation>Faculty of Pharmacy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2012-06</dateIssued><dateCreated encoding="w3cdtf">2012-01-09</dateCreated><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Aim: We aimed to determine the prevalence and characteristics of adverse drug events (ADE) in rheumatoid arthritis (RA) and (osteoarthritis) OA patients. Method: A cross‐sectional study at rheumatology clinics, was performed by random selection of RA and OA out‐patients by a research pharmacist. All suspected ADEs occurring during the last hospital visit and the subjects were identified by retrospective chart review and direct patient interview. ADE characteristics, including causative drug groups, affected organ severity and patient outcomes, were recorded. Results: One hundred and forty‐three patients consisting of 129 RA and 14 OA were recruited. The patients’ mean ages were 54.3 ± 14.3 years and 121 (84.6%) patients were female. A total of 68 ADEs were detected in 51 patients. The prevalence and rate of ADE were 35.7% and 47.6 events per 100 patients, respectively. Thirty out of 68 ADEs (44.1%) were preventable. Disease‐modifying anti‐rheumatic drugs and non‐steroidal anti‐inflammatory drugs resulted in ADEs by 41 (59.4%) and 10 (14.5%) events, respectively. Common affected organs were skin, gastrointestinal tract and eyes which accounted for 20 (29.4%), 18 (26.5%) and eight events (11.6%), respectively. Continuation of the suspected drug was noted in 42 ADEs (61.8%), classified as severity level 1 and 2a‐b, and 43 ADEs (63.2%) were completely or partially resolved during the study period. Conclusion: ADEs are common in RA and OA patients with prevalence of 35.7%. High exposure to potentially harmful drugs might explain the higher rate of ADE in these patients.</abstract><subject><genre>keywords</genre><topic>adverse drug events</topic><topic>osteoarthritis</topic><topic>outpatients</topic><topic>prevalence</topic><topic>rheumatoid arthritis</topic><topic>Thailand</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Int J Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic><topic>Original articles</topic></subject><identifier type="ISSN">1756-1841</identifier><identifier type="eISSN">1756-185X</identifier><identifier type="DOI">10.1111/(ISSN)1756-185X</identifier><identifier type="PublisherID">APL</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>315</start><end>321</end><total>7</total></extent></part></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0001"><titleInfo><title>Epidemiology of rheumatic musculoskeletal disorders in the developing world</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Chopra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Abdel‐Nasser</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chopra A, Abdel‐Nasser A (2008) Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol 22, 583–604.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>583</start><end>604</end></extent></part><relatedItem type="host"><titleInfo><title>Best Pract Res Clin Rheumatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>583</start><end>604</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0002"><titleInfo><title>Epidemiology of rheumatic disease in rural Thailand: a WHO‐ILAR COPCORD study. Community oriented programme for the control of rheumatic disease</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Chaiamnuay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Darmanwan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KD</namePart><namePart type="family">Muirden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Assawatanabodee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chaiamnuay P, Darmanwan J, Muirden KD, Assawatanabodee P (1998) Epidemiology of rheumatic disease in rural Thailand: a WHO‐ILAR COPCORD study. Community oriented programme for the control of rheumatic disease. J Rheumatol 25, 1382–7.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1382</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1382</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0003"><titleInfo><title>Burden of major musculoskeletal conditions</title></titleInfo><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Woolf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Pfleger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81, 646–56.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>646</start><end>56</end></extent></part><relatedItem type="host"><titleInfo><title>Bull World Health Organ</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>646</start><end>56</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0004"><titleInfo><title>Rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Schuna</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Pharmacotherapy: A Pathophysiologic Approach</title></titleInfo><originInfo><publisher>McGrawHill</publisher><place><placeTerm type="text">New York</placeTerm></place></originInfo><part><date>2008</date><extent unit="pages"><start>1505</start><end>18</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0005"><titleInfo><title>Osteoarthritis</title></titleInfo><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Hasnsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Elliott</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Pharmacotherapy: A Pathophysiologic Approach</title></titleInfo><originInfo><publisher>McGrawHill</publisher><place><placeTerm type="text">New York</placeTerm></place></originInfo><part><date>2005</date><extent unit="pages"><start>1692</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0006"><titleInfo><title>Rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Scott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Wolfe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TW</namePart><namePart type="family">Huizinga</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376, 1094–108.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>376</number></detail><extent unit="pages"><start>1094</start><end>108</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>376</number></detail><extent unit="pages"><start>1094</start><end>108</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0007"><titleInfo><title>Osteoarthritis</title></titleInfo><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Das</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Farooqi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Das SK, Farooqi A (2008) Osteoarthritis. Best Pract Res Clin Rheumatol 22, 657–75.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>657</start><end>75</end></extent></part><relatedItem type="host"><titleInfo><title>Best Pract Res Clin Rheumatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>657</start><end>75</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0008"><titleInfo><title>An evidence‐based update on nonsteroidal anti‐inflammatory drugs</title></titleInfo><name type="personal"><namePart type="given">CK</namePart><namePart type="family">Ong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Lirk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CH</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Seymour</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ong CK, Lirk P, Tan CH, Seymour RA (2007) An evidence‐based update on nonsteroidal anti‐inflammatory drugs. Clin Med Res 5, 19–34.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>19</start><end>34</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Med Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>19</start><end>34</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0009"><titleInfo><title>Adverse drug reactions as cause of admission to hospital: prospective analphylaxis of 18,820 patients</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Pirmohamed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">James</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Meakin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pirmohamed M, James S, Meakin S, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analphylaxis of 18,820 patients. BMJ 329, 15–9.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>15</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>BMJ</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>329</number></detail><extent unit="pages"><start>15</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0010"><titleInfo><title>What are the real lessons from Vioxx?</title></titleInfo><name type="personal"><namePart type="given">IR</namePart><namePart type="family">Edwards</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Edwards IR (2005) What are the real lessons from Vioxx? Drug Saf 28, 651–8.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>651</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>651</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0011"><titleInfo><title>COX‐2 selective inhibitors in the treatment of osteoarthritis</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Laine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WB</namePart><namePart type="family">White</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Rostom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hochberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laine L, White WB, Rostom A, Hochberg M (2008) COX‐2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 38, 165–87.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>165</start><end>87</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>165</start><end>87</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0012"><titleInfo><title>American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis</title></titleInfo><name type="personal"><namePart type="given">KG</namePart><namePart type="family">Saag</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GG</namePart><namePart type="family">Teng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NM</namePart><namePart type="family">Patkar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saag KG, Teng GG, Patkar NM, et al. (2008) American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762–84.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>762</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>762</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0013"><titleInfo><title>Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting</title></titleInfo><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Nebeker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Barach</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Samore</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140, 795–801.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>795</start><end>801</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Intern Med</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>795</start><end>801</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0014"><titleInfo><title>Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care</title></titleInfo><name type="personal"><namePart type="given">LA</namePart><namePart type="family">Thomsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AG</namePart><namePart type="family">Winterstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Sondergaard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LS</namePart><namePart type="family">Haugbolle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Melander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A (2007) Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 41, 1411–26.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1411</start><end>26</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1411</start><end>26</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0015"><titleInfo><title>Adverse drug events in ambulatory care</title></titleInfo><name type="personal"><namePart type="given">TK</namePart><namePart type="family">Gandhi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Weingart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Borus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gandhi TK, Weingart SN, Borus J, et al. (2003) Adverse drug events in ambulatory care. N Engl J Med 348, 1556–64.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1556</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1556</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0016"><titleInfo><title>Incidence and preventability of adverse drug events among older persons in the ambulatory setting</title></titleInfo><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Gurwitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TS</namePart><namePart type="family">Field</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Harrold</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gurwitz JH, Field TS, Harrold LR, et al. (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107–16.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>1107</start><end>16</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>1107</start><end>16</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0017"><titleInfo><title>Adverse drug events in cognitively impaired elderly patients</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ganjavi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Herrmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Rochon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ganjavi H, Herrmann N, Rochon PA, et al. (2007) Adverse drug events in cognitively impaired elderly patients. Dement Geriatr Cogn Disord 23, 395–400.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>395</start><end>400</end></extent></part><relatedItem type="host"><titleInfo><title>Dement Geriatr Cogn Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>395</start><end>400</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0018"><titleInfo><title>Pediatric adverse drug events in the outpatient setting: an 11‐year national analysis</title></titleInfo><name type="personal"><namePart type="given">FT</namePart><namePart type="family">Bourgeois</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KD</namePart><namePart type="family">Mandl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Valim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MW</namePart><namePart type="family">Shannon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bourgeois FT, Mandl KD, Valim C, Shannon MW (2009) Pediatric adverse drug events in the outpatient setting: an 11‐year national analysis. Pediatrics 124, e744–50.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><extent unit="pages"><start>e744</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><extent unit="pages"><start>e744</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0019"><titleInfo><title>Preventability and severity assessment in reporting adverse drug reactions</title></titleInfo><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Hartwig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Siegel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Schneider</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49, 2229–32.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>2229</start><end>32</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Hosp Pharm</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>2229</start><end>32</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0020"><titleInfo><title>Focusing on the preventability of adverse drug reactions</title></titleInfo><name type="personal"><namePart type="given">GT</namePart><namePart type="family">Schumock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Thornton</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27, 538.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>538</start></extent></part><relatedItem type="host"><titleInfo><title>Hosp Pharm</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>538</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0021"><titleInfo><title>Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug‐induced liver injuries</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Danan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Benichou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug‐induced liver injuries. J Clin Epidemiol 46, 1323–30.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1323</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Epidemiol</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1323</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0022"><titleInfo><title>Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Benichou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Danan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Flahault</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46, 1331–6.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1331</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Epidemiol</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1331</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0023"><titleInfo><title>Incidence of adverse drug events and potential adverse drug events</title></titleInfo><name type="personal"><namePart type="given">DW</namePart><namePart type="family">Bates</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Cullen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Laird</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bates DW, Cullen DJ, Laird N, et al. (2005) Incidence of adverse drug events and potential adverse drug events. JAMA 274, 29–34.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>274</number></detail><extent unit="pages"><start>29</start><end>34</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>274</number></detail><extent unit="pages"><start>29</start><end>34</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0024"><titleInfo><title>Methods for causality assessment of adverse drug reactions: a systematic review</title></titleInfo><name type="personal"><namePart type="given">TB</namePart><namePart type="family">Agbabiaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Savovic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Ernst</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31, 21–37.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>21</start><end>37</end></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>21</start><end>37</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl1716-cit-0025"><titleInfo><title>Preventing adverse drug events in hospital practice: an overview</title></titleInfo><name type="personal"><namePart type="given">MK</namePart><namePart type="family">Rommers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IM</namePart><namePart type="family">Teepe‐Twiss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Guchelaar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rommers MK Teepe‐Twiss IM, Guchelaar HJ (2007) Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 16 1129–35.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1129</start><end>35</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1129</start><end>35</end></extent></part></relatedItem></relatedItem><identifier type="istex">EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199</identifier><identifier type="ark">ark:/67375/WNG-F45C55KV-V</identifier><identifier type="DOI">10.1111/j.1756-185X.2012.01716.x</identifier><identifier type="ArticleID">APL1716</identifier><accessCondition type="use and reproduction" contentType="copyright">Journal compilation © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd© 2012 The Authors International Journal of Rheumatic Diseases © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-F45C55KV-V/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000220 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000220 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:EF7AAC0BB24AD3FD0501EC59F9AAF459E502E199
|texte= Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients
}}
| This area was generated with Dilib version V0.6.33. |  |